Advertisement
Screener

CeriBell, Inc. (CBLL) Graph

2.2 / 5 stars · 7/16 Roast Me

Add as a preferred source on Google

CBLL Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $28.10M; Cost of revenue $2.16M; Research and development $6.75M; Operating expenses $45.92M.
  • 2026-03-31: Revenue $26.49M; Cost of revenue $3.37M; Research and development $6.16M; Operating expenses $43.87M.
  • 2025-12-31: Revenue $24.78M*; Cost of revenue $3.14M*; Research and development $5.06M*; Operating expenses $36.24M*.
  • 2025-09-30: Revenue $22.59M; Cost of revenue $2.65M; Research and development $4.98M; Operating expenses $34.59M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

CBLL revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Subscription$6.86MProduct$21.24MRevenue$28.10MCost of revenue$2.16MGross profit$25.94MOperating expenses$45.92MOperating income-$19.98MOther income, net$1.15MResearch & development$6.75MPre-tax income-$19.27MIncome tax$0.00Net income-$19.27M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$28.10M$2.16M$6.75M$45.92M$0.00-$19.27M
2026-03-31$26.49M$3.37M$6.16M$43.87M(m)-$19.74M
2025-12-31$24.78M*$3.14M*$5.06M*$36.24M*(m)-$13.53M*
2025-09-30$22.59M$2.65M$4.98M$34.59M(m)-$13.46M
2025-06-30$21.20M$2.52M$4.85M$33.63M$0.00-$13.64M
2025-03-31$20.49M$2.48M$4.25M$32.21M(m)-$12.78M
2024-09-30$17.20M$2.18M$3.40M$24.95M(m)-$10.42M
2024-06-30$15.31M$2.16M$3.27M$21.59M(m)-$8.94M
2024-03-31$14.40M$2.06M$2.98M$20.80M(m)-$8.52M
2023-09-30$11.61M$1.89M$2.31M$16.89M(m)-$7.05M
2023-06-30(m)(m)(m)(m)(m)-$6.22M
2023-03-31(m)(m)(m)(m)(m)-$7.92M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$54.59M$5.53M$12.91M$89.79M$0.00-$39.01M
2025-06-30$41.69M$5.00M$9.10M$65.85M$0.00-$26.42M
2024-06-30$29.71M$4.21M$6.25M$42.39M(m)-$17.46M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$64.28M$7.65M$14.08M$100.44M(m)-$39.88M
2024-09-30$46.91M$6.40M$9.65M$67.34M(m)-$27.88M
2023-09-30$32.09M$5.05M$6.31M$48.71M$11.00K-$21.19M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$89.06M$10.79M$19.14M$136.68M$0.00-$53.41M
2024-12-31$65.44M$8.69M$13.56M$96.46M$0.00-$40.45M
2023-12-31$45.23M$7.06M$8.99M$68.20M$11.00K-$29.46M

Similar stocks

Stock NameCountryMarket CapPE Ratio
CONMED Corp (CNMD)United States$1.353B26.72
CapsoVision, Inc (CV)United States$0.310B-12.68
Electromed, Inc. (ELMD)United States$0.233B31.13
EDAP TMS SA (FOCL)$0.171B
Stereotaxis, Inc. (STXS)United States$0.130B-7.53
Vivani Medical, Inc. (VANI)United States$0.111B
electroCore, Inc. (ECOR)United States$0.102B
Neuraxis, INC (NRXS)United States$0.097B
Nexalin Technology, Inc. (NXL)United States$0.094B
Streamex Corp. (STEX)United States$0.089B-0.19
Advertisement